摘要
目的探讨采用度拉糖肽注射液治疗肥胖型糖尿病的有效性及安全性。方法选取2020年7月—2022年5月相城人民医院接诊治疗的93例肥胖型2型糖尿病患者为研究对象,根据随机编号奇偶结果划分为观察组(奇数编号,47例)与对照组(偶数编号,46例)。对照组治疗方案为单用降糖药物二甲双胍,观察组治疗方案为二甲双胍联合度拉糖肽,两组均持续用药3个月。检测并对比两组患者入院时、用药3个月后血糖、血脂指标水平,记录比较两组患者治疗前后体质量、腰围及BMI指数变化情况,观察统计两组患者治疗期间的不良反应发生情况。结果治疗后,两组血糖、血脂水平均改善,且观察组空腹血糖、餐后2 h血糖、糖化血红蛋白、TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组,差异有统计学意义(P<0.05)。观察组体质量、腰围、BMI均低于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论临床治疗肥胖型糖尿病时可在二甲双胍降糖用药的基础上联用度拉糖肽,对调控血脂水平效果明显,能有效降低患者体质量,且安全性佳。
Objective To explore the efficacy and safety of Dulagopeptide injection in the treatment of obese diabetes‐Methods 93 obese type 2 diabetes patients who were treated in Xiangcheng People's Hospital from July 2020 to May 2022 were selected as the study subjects.According to the odd even results of random number,they were divided into the observation group(odd number,47 cases)and the control group(even number,46 cases).The treatment plan of the control group was metformin alone,and the treatment plan of the observation group was metformin combined with dulaglutide,and both groups continued to be treated for 3 months.Detected and compared the levels of blood glucose and blood lipid indexes of the two groups of patients at the time of admission and after 3 months of medication,recorded and compared the changes of body mass,waist circumference and BMI index of the two groups of patients before and after treatment,and observed and counted the adverse reactions of the two groups of patients during treatment.Results After treatment,the blood glucose and blood lipid levels in both groups improved,and the fasting blood glucose,2-hour postprandial blood glucose,glycosylated hemoglobin,TC,TG,LDL-C levels in the observation group were lower than those in the control group,while HDL-C levels were higher than that in the control group,the difference was statistically significant(P<0.05).The body mass,waist circumference and BMI of the observation group were lower than those of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In clinical treatment of obese diabetes,dulaglutide can be used in combination with metformin on the basis of hypoglycemic drugs,which has obvious effect on regulating blood lipid levels,can effectively reduce the body mass of patients,and has good safety.
作者
程吉
杜守作
奚雯菲
CHENG Ji;DU Shouzuo;XI Wenfei(Department of Endocrinology,Xiangcheng People's Hospital,Suzhou,Jiangsu Province,215131 China)
出处
《糖尿病新世界》
2023年第1期77-80,共4页
Diabetes New World Magazine
关键词
度拉糖肽
肥胖型糖尿病
血糖值
血脂指标
Dulatoseptide
Obesity diabetes mellitus
Blood glucose value
Lipid index
